Immediate Impact
55 standout
Citing Papers
From ex vivo to in vivo chimeric antigen T cells manufacturing: new horizons for CAR T-cell based therapy
2025 Standout
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Works of Noa Biran being referenced
Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).
2021
A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Noa Biran | 308 | 246 | 217 | 87 | 405 | |
| Omar Nadeem | 248 | 215 | 250 | 75 | 430 | |
| Alissa Visram | 225 | 149 | 188 | 55 | 371 | |
| Danai Dima | 163 | 154 | 206 | 66 | 351 | |
| Yoshiaki Kuroda | 219 | 202 | 160 | 35 | 394 | |
| Yogesh Jethava | 246 | 197 | 146 | 50 | 405 | |
| Hamza Hashmi | 187 | 162 | 249 | 99 | 436 | |
| Vladimir Vorobyev | 217 | 178 | 133 | 37 | 360 | |
| Toshiki Terao | 147 | 133 | 107 | 59 | 361 | |
| Valentina Marchica | 218 | 174 | 230 | 36 | 416 | |
| Zahra Mahmoudjafari | 145 | 113 | 282 | 71 | 402 |
All Works
Login with ORCID to disown or claim papers
Loading papers...